These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 25769011)
41. Encapsulation of cationic ruthenium complexes into a chiral self-assembled cage. Fiedler D; Pagliero D; Brumaghim JL; Bergman RG; Raymond KN Inorg Chem; 2004 Feb; 43(3):846-8. PubMed ID: 14753801 [TBL] [Abstract][Full Text] [Related]
42. Binding sites of [Ru(bpy)2(H2O)2](BF4)2 with sulfur- and histidine-containing peptides studied by electrospray ionization mass spectrometry and tandem mass spectrometry. Hong J; Miao Y; Miao R; Yang G; Tang H; Guo Z; Zhu L J Mass Spectrom; 2005 Jan; 40(1):91-9. PubMed ID: 15619262 [TBL] [Abstract][Full Text] [Related]
43. A comparison of the binding of metal complexes to duplex and quadruplex DNA. Talib J; Green C; Davis KJ; Urathamakul T; Beck JL; Aldrich-Wright JR; Ralph SF Dalton Trans; 2008 Feb; (8):1018-26. PubMed ID: 18274682 [TBL] [Abstract][Full Text] [Related]
44. A mass spectrometric investigation of the ability of metal complexes to modulate transcription factor activity. Talib J; Beck JL; Urathamakul T; Nguyen CD; Aldrich-Wright JR; Mackay JP; Ralph SF Chem Commun (Camb); 2009 Oct; (37):5546-8. PubMed ID: 19753352 [TBL] [Abstract][Full Text] [Related]
45. A mass spectrometric investigation of non-covalent interactions between ruthenium complexes and DNA. Urathamakul T; Beck JL; Sheil MM; Aldrich-Wright JR; Ralph SF Dalton Trans; 2004 Sep; (17):2683-90. PubMed ID: 15514752 [TBL] [Abstract][Full Text] [Related]
46. Cytotoxicity of half sandwich ruthenium(II) complexes with strong hydrogen bond acceptor ligands and their mechanism of action. Das S; Sinha S; Britto R; Somasundaram K; Samuelson AG J Inorg Biochem; 2010 Feb; 104(2):93-104. PubMed ID: 19913918 [TBL] [Abstract][Full Text] [Related]
47. Elucidation of the binding sites of two novel Ru(II) complexes on bovine serum albumin. Nišavić M; Masnikosa R; Butorac A; Perica K; Rilak A; Korićanac L; Hozić A; Petković M; Cindrić M J Inorg Biochem; 2016 Jun; 159():89-95. PubMed ID: 26970034 [TBL] [Abstract][Full Text] [Related]
48. Electrospray ionization mass spectrometry of oligonucleotide complexes with drugs, metals, and proteins. Beck JL; Colgrave ML; Ralph SF; Sheil MM Mass Spectrom Rev; 2001; 20(2):61-87. PubMed ID: 11455562 [TBL] [Abstract][Full Text] [Related]
49. Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. Webb MI; Wu B; Jang T; Chard RA; Wong EW; Wong MQ; Yapp DT; Walsby CJ Chemistry; 2013 Dec; 19(50):17031-42. PubMed ID: 24203647 [TBL] [Abstract][Full Text] [Related]
50. Biological activity and binding properties of [Ru(II)(dcbpy)2Cl2] complex to bovine serum albumin, phospholipase A2 and glutathione. Nešić M; Popović I; Leskovac A; Petković M Biometals; 2016 Oct; 29(5):921-33. PubMed ID: 27515969 [TBL] [Abstract][Full Text] [Related]
52. Medicinal organometallic chemistry: designing metal arene complexes as anticancer agents. Peacock AF; Sadler PJ Chem Asian J; 2008 Nov; 3(11):1890-9. PubMed ID: 18712745 [TBL] [Abstract][Full Text] [Related]
53. Conjugation of a Ru(II) arene complex to neomycin or to guanidinoneomycin leads to compounds with differential cytotoxicities and accumulation between cancer and normal cells. Grau-Campistany A; Massaguer A; Carrion-Salip D; Barragán F; Artigas G; López-Senín P; Moreno V; Marchán V Mol Pharm; 2013 May; 10(5):1964-76. PubMed ID: 23510087 [TBL] [Abstract][Full Text] [Related]
54. fac-{Ru(CO)(3)}(2+) selectively targets the histidine residues of the beta-amyloid peptide 1-28. Implications for new Alzheimer's disease treatments based on ruthenium complexes. Valensin D; Anzini P; Gaggelli E; Gaggelli N; Tamasi G; Cini R; Gabbiani C; Michelucci E; Messori L; Kozlowski H; Valensin G Inorg Chem; 2010 Jun; 49(11):4720-2. PubMed ID: 20459130 [TBL] [Abstract][Full Text] [Related]
55. Anti-tumour activity in non-small cell lung cancer models and toxicity profiles for novel ruthenium(II) based organo-metallic compounds. Guichard SM; Else R; Reid E; Zeitlin B; Aird R; Muir M; Dodds M; Fiebig H; Sadler PJ; Jodrell DI Biochem Pharmacol; 2006 Feb; 71(4):408-15. PubMed ID: 16360645 [TBL] [Abstract][Full Text] [Related]
56. Organometallic Ru(II) Photosensitizers Derived from π-Expansive Cyclometalating Ligands: Surprising Theranostic PDT Effects. Sainuddin T; McCain J; Pinto M; Yin H; Gibson J; Hetu M; McFarland SA Inorg Chem; 2016 Jan; 55(1):83-95. PubMed ID: 26672769 [TBL] [Abstract][Full Text] [Related]
57. Multinuclear Organometallic Ruthenium-Arene Complexes for Cancer Therapy. Babak MV; Ang WH Met Ions Life Sci; 2018 Feb; 18():. PubMed ID: 29394025 [TBL] [Abstract][Full Text] [Related]
58. From hydrolytically labile to hydrolytically stable Ru(II)-arene anticancer complexes with carbohydrate-derived co-ligands. Hanif M; Meier SM; Kandioller W; Bytzek A; Hejl M; Hartinger CG; Nazarov AA; Arion VB; Jakupec MA; Dyson PJ; Keppler BK J Inorg Biochem; 2011 Feb; 105(2):224-31. PubMed ID: 21194622 [TBL] [Abstract][Full Text] [Related]
59. Competitive reactions of a ruthenium arene anticancer complex with histidine, cytochrome c and an oligonucleotide. Wang F; Bella J; Parkinson JA; Sadler PJ J Biol Inorg Chem; 2005 Mar; 10(2):147-55. PubMed ID: 15735959 [TBL] [Abstract][Full Text] [Related]